Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomised, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Authors
Cwynarski, K.Elsawy, M.
Chavez, J. C.
Avivi, I.
Larouche, J. F.
Wannesson, L.
Osman, K.
Davison, K.
Rudzki, J. D.
Dahiya, S.
Dorritie, K.
Jaglowski, S.
Radford, J.
Morschhauser, F.
Cunningham, D.
Garcia-Sancho, A. M.
Tzachanis, D.
Ulrickson, M. L.
Karmali, R.
Kekre, N.
Thieblemont, C.
Enblad, G.
Dreger, P.
Malladi, R.
Joshi, N.
Wang, W. J.
Solem, C. T.
Snider, J. T.
To, C.
Kersten, M. J.
Issue Date
2022